International Journal of Hematology · 2023 · 13 citations · 19 references
MedicinePharmacotherapyClinical EpidemiologyHemostasisPhysical ActivityAnticoagulant ManagementBleeding DisordersHemorrhage ControlPharmacoepidemiologyBleedBleedingPatient-reported Outcome MonitoringSerious Adverse EventsWearable Activity MonitoringWearable Activity MonitorsWearable Activity TrackersWearable Activity Tracking
INTRODUCTION: Little information exists on the relationship between bleeding outcomes and physical activity in patients with haemophilia A (PwHA). AIM: This interim analysis of the TSUBASA study (UMIN-CTR ID: UMIN000037448) evaluated the association of physical activity with bleeding and safety in PwHA starting emicizumab. METHODS: PwHA without factor VIII inhibitors were recruited. Physical activity and bleed data were obtained using an electronic patient-reported outcome application and wearable activity tracker. Adverse events (AEs) were documented. RESULTS: At data cut-off (31-May-2021), 107 PwHA were enrolled, with a median (range) age of 35 (0-73) years. Physical activity data were obtained for 74 participants. Of these, 47 (63.5%) recorded a total of 396 exercise events. The most common exercise events were walking (32.4%), cycling (14.9%), and football (5.4%). Two (0.5%) exercise events in the same individual were associated with bleeding (running, weight training). The safety analysis population consisted of 106 participants treated with emicizumab (median observation period: 241.5 days). Twenty-one (19.8%) participants experienced a total of 39 AEs. Five (4.7%) experienced a serious AE, none of which was emicizumab-related, and three (2.8%) experienced an adverse drug reaction. CONCLUSIONS: PwHA receiving emicizumab in the TSUBASA study experienced minimal bleeding associated with physical activity. TRIAL REGISTRATION: Trial registration: UMIN-CTR ID: UMIN000037448.
19
Physical Activity and Public Health
William L. Haskell, I‐Min Lee, Russell R. Pate et al. · Medicine & Science in Sports & Exercise · 2007 · 4.6K citations
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava, Elena Santagostino, Alison Dougall et al. · Haemophilia · 2020 · 1.9K citations · Full text
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text
Medicine, Hematology, Pharmacology +16